Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: Atazanavir, Nelfinavir mesylate; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 47
States / cities: Little Rock, Arkansas • Berkeley, California • Fountain Valley, California + 37 more

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more

Conditions: HIV Infections
Interventions: EVG, RTV, ARV regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: Not listed
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 47
States / cities: Pheonix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 44 more

Conditions: Non Small Cell Lung Cancer
Interventions: Nelfinavir; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: Indinavir sulfate, Abacavir sulfate, Nelfinavir mesylate, Efavirenz, Nevirapine, Lamivudine, Stavudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 1,710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 17
States / cities: San Francisco, California • Denver, Colorado • New Haven, Connecticut + 13 more

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Delavirdine mesylate, Stavudine, Didanosine; Drug
Lead sponsor: Pharmacia and Upjohn; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Peapack, New Jersey

Conditions: HIV Infections
Interventions: Medroxyprogesterone acetate, Estradiol; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Ovarian Cancer
Interventions: Hydroxychloroquine, Nelfinavir, Bevacizumab; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Lamivudine, Filgrastim, Stavudine, Cyclophosphamide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: HIV Infections
Interventions: Nelfinavir, Efavirenz; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Systemic Lupus Erythematosus
Interventions: Nelfinavir; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 8
States / cities: Los Angeles, California • Chicago, Illinois • Manhasset, New York + 2 more

Conditions: Healthy Volunteers
Interventions: Nelfinavir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 2
States / cities: New Haven, Connecticut • Ann Arbor, Michigan

Conditions: HIV Infections
Interventions: Ritonavir, Nelfinavir mesylate, Nevirapine, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 21 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 59
States / cities: Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 42 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Nelfinavir; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: HIV Infections
Interventions: FDA Approved Antiretroviral Therapy (see list below); Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 5
States / cities: San Diego, California • San Francisco, California • Baltimore, Maryland + 2 more

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Nevirapine, Stavudine; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: San Francisco, California • Providence, Rhode Island

Conditions: HIV Infections
Interventions: Abacavir sulfate, Nelfinavir mesylate, Nevirapine, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 15 Days to 2 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 12
States / cities: Gainesville, Florida • New Orleans, Louisiana • Baltimore, Maryland + 8 more

Conditions: HIV Infection
Interventions: Nelfinavir mesylate, 625 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Jacksonville, Florida • Miami, Florida • Metairie, Louisiana + 2 more

Conditions: HIV-1-infection
Interventions: Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 40
States / cities: Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more

Conditions: HIV Infections, Pregnancy
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 31
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more

Conditions: Disease Transmission, Vertical, Vertical Human Immunodeficiency Virus Transmission, HIV Infections
Interventions: Zidovudine, Nevirapine (NVP), Epivir (3TC), Nelfinavir (NFV); Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Up to 2 Days
Enrollment: 1,735 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2011
U.S. locations: 5
States / cities: Long Beach, California • Gainesville, Florida • Jacksonville, Florida + 2 more

Conditions: Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer
Interventions: gemcitabine hydrochloride, leucovorin calcium, fluorouracil, nelfinavir mesylate, stereotactic body radiation therapy, hypofractionated radiation therapy, therapeutic conventional surgery; Drug · Radiation · Procedure
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: HIV Infections, Lipodystrophy
Interventions: Nelfinavir mesylate, Stavudine, Lamivudine, Efavirenz; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Saquinavir; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 16 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: San Diego, California • New Haven, Connecticut • Kansas City, Missouri + 5 more

Search by objective public record fields.

A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor

A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III Non Small Cell Lung Cancer (NSCLC)

A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients

Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women

Autophagy Maintenance (AUTOMAIN)

A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients

Mechanisms of Lipodystrophy in HIV-Infected Pateints

Nelfinavir in Systemic Lupus Erythematosus

Thorough QT Study of Nelfinavir

A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment

Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer

Clinical Trial of CNS-targeted HAART (CIT2)

The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine

Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection

Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

A Study of HIV Levels During Pregnancy and After Childbirth

Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission

Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy

A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs